On the recordJanuary 31, 2012
The reauthorization of the FDA user fee program presents Congress with the opportunity to improve upon the current U.S. drug and device approval pathway.
Source
congress.govThe reauthorization of the FDA user fee program presents Congress with the opportunity to improve upon the current U.S. drug and device approval pathway.
Gingrey emphasizes the chance to enhance drug approval processes through reauthorization.
Share
More from Phil Gingrey
I assure you that there is a plan. There may be a few people in this town that want to pretend that there is no plan. But there is.
I really have to commend the FDA on that and realizing the desire and need for new antibiotics and acting quickly to implement the program.
As educators and legislators, we must not neglect our duties to equip these young people, our children, these students, with the tools and the knowledge to build a successful career.
All of these mandates, all this mandated coverage, comes at a tremendous price.